Sort
48,018 grants matching “immunotherapy”
Novel immunotherapeutic potential of DGKalpha inhibition for glioblastoma
$387,027Benjamin W. Purow · University Of Virginia · R01 · FY2024 · NS
Epigenetic Regulation of Plasma Cells Differentiation
$387,009Jeremy M. Boss · Emory University · R01 · FY2017 · AI
Immunomodulatory Biomaterials via Peptide and Protein Self-Assembly
$387,007Joel H Collier · Duke University · R01 · FY2018 · EB
Research Training in Hematology
$387,006John Patrick Sheehan · University Of Wisconsin-Madison · T32 · FY2020 · HL
MECHANISMS OF NONSTERILIZING IMMUNITY IN MALARIA
$387,006University Of Wisconsin Madison · R01 · FY2002 · AI
Targeted delivery of multimodal therapy for reducing prostate cancer disparity
$386,974Runhua Runa Liu · University Of Alabama At Birmingham · R01 · FY2022 · CA
T cell plasticity, fusion proteins and CAR T cell-based immunotherapy of head and neck cancer
$386,970Soldano Ferrone · Massachusetts General Hospital · R01 · FY2021 · DE
T cell plasticity, fusion proteins and CAR T cell-based immunotherapy of head and neck cancer
$386,970Soldano Ferrone · Massachusetts General Hospital · R01 · FY2020 · DE
T cell plasticity, fusion proteins and CAR T cell-based immunotherapy of head and neck cancer
$386,970Soldano Ferrone · Massachusetts General Hospital · R01 · FY2019 · DE
Biochemistry of Apoptosis in CLL
$386,950John C Reed · University Of California, San Diego · P01 · FY2010 · CA
Transgenesis and Xenotransplantation
$386,950Jorge A. Piedrahita · North Carolina State University Raleigh · R01 · FY2010 · HL
TREATMENT OF AUTOIMMUNITY WITH REGULATORY T LYMPHOCYTES
$386,944Terrence L Geiger · St. Jude Children'S Research Hospital · R01 · FY2013 · AI
Molecular mechanisms of signaling co-ordination in innate lymphocytes
$386,888Subramaniam Malarkannan · Medical College Of Wisconsin · R01 · FY2016 · AI
A Novel Microbiome-Based Immune-Modulator that Potentiates Cancer Checkpoint Therapy
$386,860Gary Fanger · Rise Therapeutics, Llc · R44 · FY2021 · CA
Role of the tumor NLRP3 inflammasome in the generation of anti-PD-1 antibody immunotherapy-associated toxicities
$386,846Brent Allen Hanks · Duke University · R01 · FY2022 · CA
Targeting the Epigenome for Lung Cancer Therapy
$386,838David Schrump · Division Of Clinical Sciences - Nci · ZIA · FY2015 · CA
Targeting Syk to enhance anti-tumor immune responses in neuroblastoma
$386,825Shweta Joshi · University Of California, San Diego · R01 · FY2024 · NS
Optimizing Therapeutic STING Agonism in Triple Negative Breast Cancer
$386,817Thanh Uyen Barbie · Dana-Farber Cancer Inst · R01 · FY2024 · CA
Antigen-independent prediction and biomarker identification of cancer-specific T cells
$386,817Bo Li · Children'S Hosp Of Philadelphia · R01 · FY2024 · CA
Liquid biopsy in myeloma to inform outcome and treatment decisions
$386,817Jens G Lohr · Dana-Farber Cancer Inst · R37 · FY2024 · CA
Desensitization of Human Mast Cells and Basophils: Mechanisms and Potential Utili
$386,816Lawrence Barry Schwartz · Virginia Commonwealth University · U19 · FY2012 · AI
The immunoPeptidoGenomic (iPepGen) informatics resource forimmuno-oncology research
$386,780Timothy J. Griffin · University Of Minnesota · U01 · FY2025 · CA
Analysis of peripheral tolerance in vivo
$386,760Marc K. Jenkins · University Of Minnesota · P01 · FY2016 · AI
Epigenetic Therapy for Thoracic Malignanceis
$386,745David Schrump · Division Of Clinical Sciences - Nci · ZIA · FY2017 · CA
Advanced development and validation of genome-scale molecular diagnostics for microsatelliteinstability using targeted molecular counting methods
$386,677Stephen J Salipante · University Of Washington · R33 · FY2018 · CA